Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, ...

A new groundbreaking study revealed that Remibrutinib showed promising results in treating chronic spontaneous urticaria.A recent study published in the New England Journal of Medicine outlined the ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

Celltrion, a major South Korean biopharmaceutical firm, on Thursday said it has launched its biosimilar product for Stelara, a ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

Dr Ruchi Gupta shares key updates including a new anaphylaxis definition, treatment advances, and emerging biologics for CSU.

Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos' financial outlook, restructuring activities and estimated cash outlook as reported by ...

The advent of remibrtuinib, a Bruton's tyrosine kinase inhibitor, may encourage dermatologists to take care of chronic spontaenous urticaria patients, says a presenter at the 2025 meeting of the ...

Celltrion’s Omlyclo is interchangeable with Xolair to treat the same conditions: asthma, chronic rhinosinusitis, food allergy ...